Elena H. Ridloff | Alexion Pharmaceuticals, Inc. |
Ludwig N. Hantson | Alexion Pharmaceuticals, Inc. |
Paul J. Clancy | Alexion Pharmaceuticals, Inc. |
Brian Goff | Alexion Pharmaceuticals, Inc. |
John J. Orloff | Alexion Pharmaceuticals, Inc. |
Eric Schmidt | Cowen and Co. LLC |
Alethia Young | Credit Suisse Securities (NYSE:USA) LLC |
Geoffrey Meacham | Barclays Capital, Inc. |
Terence Flynn | Goldman Sachs & Co. LLC |
Geoffrey C. Porges | Leerink Partners LLC |
Matthew K. Harrison | Morgan Stanley & Co. LLC |
Christopher Raymond | Piper Jaffray |
Robyn Karnauskas | Citigroup Global Markets, Inc. |
Ying Huang | Bank of America Merrill Lynch |
Anupam Rama | JPMorgan Securities LLC |
Andrew Peters | Deutsche Bank Securities, Inc. |
M. Ian Somaiya | BMO Capital Markets (United States) |
Kennen Mackay | RBC Capital Markets LLC |
Good morning, everyone, and welcome to the Alexion Pharmaceuticals, Incorporated Third Quarter 2017 Conference Call. Today's conference is being recorded.
For opening remarks and introductions, I would like to turn the call over to Elena Ridloff, Vice President, Investor Relations. Please go ahead, ma'am.
Thank you, Rebecca.